Davenport & Co’s Aratana Therapeutics, Inc. PETX Stock Holding History

Davenport & Co’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-50,750	Closed	-$262K	–	779
2019 Q3	$262K	Hold	50,750	–	–	﹤0.01%	594
2019 Q2	$262K	Sell	50,750 -35,500	-41%	-$160K	﹤0.01%	595
2019 Q1	$311K	Sell	86,250 -5,000	-5%	-$21.7K	﹤0.01%	529
2018 Q4	$559K	Sell	91,250 -42,000	-32%	-$256K	0.01%	378
2018 Q3	$778K	Sell	133,250 -11,500	-8%	-$57.5K	0.01%	353
2018 Q2	$615K	Sell	144,750 -28,378	-16%	-$143K	0.01%	399
2018 Q1	$763K	Sell	173,128 -3,872	-2%	-$17.3K	0.01%	361
2017 Q4	$931K	Sell	177,000 -1,000	-0.6%	-$6.12K	0.01%	329
2017 Q3	$1.09M	Buy	178,000 +106,000	+147%	+$671K	0.01%	294
2017 Q2	$521K	Buy	+72,000	New	+$443K	0.01%	416

Davenport & Co's PETX Position: Q4 2019 in Review

Davenport & Co sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2019, closing a stake of 50,750 shares — an estimated $262K sold.

Davenport & Co first reported a position in PETX in Q2 2017 and held it in 10 quarters. The position peaked at $1.09M in Q3 2017. 0 funds tracked by Wall St. Rank hold PETX as of Q4 2019.

Davenport & Co reported no remaining Aratana Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Davenport & Co sold 50,750 Aratana Therapeutics, Inc. shares in Q4 2019, an estimated $262K.
Davenport & Co first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 10 quarters.
Davenport & Co's Aratana Therapeutics, Inc. position peaked at $1.09M in Q3 2017.
0 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2019.

Based on Davenport & Co's 13F filing for Q4 2019, filed 22 Jan 2020.